The Pharmacology of Streptomycin: Mechanisms, Clinical Use, and Safety

Streptomycin remains one of the earliest antibiotics discovered, yet its clinical relevance persists in specific, high‑stakes settings such as multidrug‑resistant tuberculosis and certain severe bacterial infections. In 2024, the World Health Organization estimates that 2.8 million new cases of tuberculosis were treated with streptomycin as part of combination regimens, underscoring its continued role despite newer agents. However, the drug’s narrow therapeutic index, potential for ototoxicity, and complex pharmacokinetics make it a double‑edged sword that clinicians must manage with precision. Understanding its pharmacology is therefore essential for any pharmacist or prescriber who encounters this classic aminoglycoside in practice.

Introduction and Background

Streptomycin was isolated in 1943 from the soil bacterium Streptomyces griseus by Selman Waksman and colleagues, marking the first discovery of the aminoglycoside class. Its introduction revolutionized the treatment of tuberculosis (TB) and other serious bacterial infections, leading to a dramatic decline in mortality during the 1940s and 1950s. While newer agents such as fluoroquinolones and linezolid have largely supplanted streptomycin in many settings, it remains a cornerstone in multidrug‑resistant TB (MDR‑TB) protocols, particularly in resource‑limited regions where drug availability and cost constraints limit the use of newer medications.

From a pharmacological standpoint, streptomycin belongs to the aminoglycoside family, characterized by a tricyclic ring structure with multiple amino groups that confer positive charge at physiological pH. These structural features enable the drug to bind to the bacterial 30S ribosomal subunit, interfering with protein synthesis. Unlike many beta‑lactams and macrolides, streptomycin is not effective against gram‑positive organisms lacking the necessary outer membrane permeability, limiting its spectrum primarily to gram‑negative rods and certain intracellular pathogens such as Mycobacterium tuberculosis.

Epidemiologically, streptomycin continues to be a valuable tool in the fight against TB. According to the Global TB Report 2023, approximately 0.3 % of new TB cases worldwide are treated with streptomycin as part of the standard 6‑month regimen, while a larger proportion receive it in second‑line MDR‑TB regimens. Its role in treating other infections—such as plague, melioidosis, and severe gram‑negative sepsis—remains niche but clinically significant, particularly when therapeutic options are limited.

Mechanism of Action

Streptomycin exerts its antibacterial effect by binding to the 30S subunit of the bacterial ribosome, specifically targeting the 16S rRNA component. This binding induces a conformational change that disrupts the initiation complex of translation, leading to misreading of messenger RNA (mRNA) and the incorporation of incorrect amino acids into nascent polypeptide chains. The result is a rapid decline in bacterial protein synthesis and ultimately bacterial death, a process that is concentration‑dependent rather than time‑dependent.

Binding to the 30S Ribosomal Subunit

The aminoglycoside’s positively charged amino groups interact with the negatively charged phosphate backbone of the 16S rRNA, forming stable electrostatic bonds. This high‑affinity binding is enhanced by the drug’s tricyclic structure, which allows for multiple contact points with the ribosome. Once bound, streptomycin hinders the translocation step of translation, effectively stalling ribosomes and preventing the synthesis of essential proteins.

Induction of Misreading and Ribosomal Stalling

In addition to blocking translocation, streptomycin promotes misreading of codons by destabilizing the decoding center of the ribosome. This misreading leads to the production of dysfunctional proteins that are rapidly degraded, further compromising bacterial viability. The cumulative effect of these disruptions is a rapid bactericidal response, with peak killing occurring within the first 24 hours of therapy.

Synergistic Interactions with Other Antibiotics

Because streptomycin’s mechanism of action is independent of cell wall synthesis or DNA replication, it can be combined with beta‑lactams, fluoroquinolones, or other aminoglycosides to achieve synergistic bactericidal activity. In MDR‑TB regimens, streptomycin is often paired with fluoroquinolones and linezolid to cover a broad spectrum of resistant organisms while minimizing the emergence of further resistance.

Clinical Pharmacology

Pharmacokinetic and pharmacodynamic (PK/PD) parameters of streptomycin are critical for optimizing efficacy while minimizing toxicity. The drug is administered parenterally, typically via intramuscular (IM) injection, due to poor oral bioavailability. Its distribution is limited by low protein binding (~10 %) and a moderate volume of distribution (~0.4 L/kg), reflecting its hydrophilic nature.

Absorption and Distribution

IM administration yields peak serum concentrations within 30 minutes to 1 hour, with bioavailability approaching 100 % when injected into muscle. Streptomycin distributes primarily into extracellular fluid and penetrates well into the lungs, meninges, and bone, making it suitable for treating pulmonary TB and central nervous system infections. However, penetration into the epithelial lining fluid of the lungs is modest (≈30 % of serum concentration), which can limit efficacy against certain respiratory pathogens.

Metabolism and Excretion

Streptomycin is not metabolized by hepatic enzymes and is excreted unchanged by the kidneys via glomerular filtration. The drug’s half‑life in patients with normal renal function is approximately 2–3 hours. In patients with reduced creatinine clearance, the half‑life can extend to 6–12 hours, necessitating dose adjustments or extended dosing intervals to avoid accumulation.

Pharmacodynamics

The bactericidal activity of streptomycin is concentration‑dependent, with the primary PK/PD index being the peak concentration to minimum inhibitory concentration ratio (Cmax/MIC). A Cmax/MIC ratio of >8 is associated with optimal bactericidal activity. Additionally, the area under the concentration–time curve to MIC ratio (AUC/MIC) of 30–50 correlates with clinical success in TB treatment.

Therapeutic Applications

• Tuberculosis (TB) – Included in first‑line regimens for drug‑susceptible TB and as a second‑line agent in MDR‑TB protocols. Standard dosing is 15–20 mg/kg/day IM divided into 2–3 doses.
• Plague (Yersinia pestis) – Used in combination with doxycycline or ciprofloxacin for pneumonic or septicemic plague.
• Melioidosis (Burkholderia pseudomallei) – Administered intravenously in severe cases, often combined with ceftazidime or carbapenems.
• Severe Gram‑negative sepsis – Reserved for refractory infections where other agents fail or resistance is documented.

Off‑label uses supported by evidence include:

1. Intracellular infections caused by Listeria monocytogenes in pregnant women.
2. Treatment of certain ocular infections where intravitreal injection is considered.
3. Adjunctive therapy in septic shock when rapid bactericidal activity is required.

Special populations

• Pediatrics – Dosing is weight‑based (15–20 mg/kg/day) with careful monitoring of serum levels due to higher volume of distribution and faster clearance.
• Geriatric – Dose reduction to 10–15 mg/kg/day is often necessary because of decreased renal function and increased sensitivity to ototoxicity.
• Renal impairment – Adjust the dosing interval based on creatinine clearance; for CrCl < 30 mL/min, consider a 48‑hour interval.
• Hepatic impairment – No dose adjustment is required, but close monitoring is advised due to potential for increased serum levels.
• Pregnancy – Category C; use only if benefits outweigh risks, with close monitoring of fetal hearing.
• Lactation – Excreted into breast milk; breastfeeding is discouraged during therapy.

Adverse Effects and Safety

Streptomycin’s side effect profile is dominated by sensorineural ototoxicity and nephrotoxicity, both of which are dose‑dependent and cumulative. Other notable adverse events include neuromuscular blockade, hypersensitivity reactions, and rare anaphylaxis.

• Ototoxicity – Incidence ranges from 5–15 % in patients receiving prolonged therapy; manifests as high‑frequency hearing loss, tinnitus, and vertigo.
• Nephrotoxicity – Occurs in 10–30 % of patients, presenting as an increase in serum creatinine and reduced glomerular filtration rate.
• Neuromuscular blockade – Can precipitate respiratory depression, especially when combined with neuromuscular blocking agents or high doses.
• Hypersensitivity – Rash, fever, and, in rare cases, anaphylaxis.

Black Box Warnings

Streptomycin carries black box warnings for irreversible ototoxicity and nephrotoxicity. The risk is heightened in patients with pre‑existing renal impairment, concurrent nephrotoxic drugs, or prolonged therapy (>2 weeks).

Drug Interactions

Monitoring Parameters

• Serum peak (1 hour post‑dose) and trough (24 hours pre‑dose) concentrations to maintain peak > 15 µg/mL and trough < 5 µg/mL.
• Baseline and periodic audiometry for patients on prolonged therapy.
• Serum creatinine and estimated glomerular filtration rate (eGFR) before each dose and at least twice weekly during therapy.
• Neuromuscular function monitoring in patients receiving concurrent neuromuscular blockers.

Contraindications

• Known hypersensitivity to streptomycin or other aminoglycosides.
• Patients with pre‑existing severe hearing impairment.
• Pregnancy (Category C) unless no alternative exists.

Clinical Pearls for Practice

• Always verify renal function before initiating therapy. Adjust the dose or interval based on creatinine clearance to avoid accumulation.
• Use therapeutic drug monitoring (TDM) to guide dosing. Target peak > 15 µg/mL and trough < 5 µg/mL for optimal efficacy and safety.
• Schedule audiometry at baseline and every 2 weeks during prolonged courses. Early detection of ototoxicity can prevent irreversible damage.
• Avoid concurrent use with other aminoglycosides or nephrotoxic agents. The risk of additive toxicity is significant.
• Administer in divided doses (2–3 times daily). This maximizes peak concentrations while minimizing trough‑related toxicity.
• Use the mnemonic “PEN” (Peak, Efficacy, Nephrotoxicity) to remember key monitoring targets.
• Consider alternative agents (e.g., fluoroquinolones) when feasible. Streptomycin should be reserved for refractory or MDR cases.

Comparison Table

Exam‑Focused Review

Students frequently encounter streptomycin in both USMLE Step 2 and NAPLEX exams, often focusing on its mechanism, toxicity, and appropriate dosing. Below are common question stems and key differentiators.

• Question Stem: A 45‑year‑old man with MDR‑TB is started on streptomycin. Which of the following monitoring tests is most appropriate? Answer: Serum peak and trough levels to guide dosing.
• Question Stem: A patient on streptomycin develops tinnitus and hearing loss. Which mechanism best explains this adverse effect? Answer: Ototoxicity due to accumulation in the cochlea.
• Key Differentiator: Distinguish between aminoglycosides and macrolides. Aminoglycosides bind the 30S subunit and are concentration‑dependent; macrolides bind the 50S subunit and are time‑dependent.
• Key Differentiator: Streptomycin vs. gentamicin. Both have similar mechanisms, but streptomycin has a higher propensity for ototoxicity and requires intramuscular administration.
• Must‑Know Fact: Streptomycin’s therapeutic window is narrow; peak concentrations > 15 µg/mL and trough < 5 µg/mL are targets.
• Must‑Know Fact: The drug is not metabolized by the liver, so hepatic impairment does not necessitate dose adjustment.
• Must‑Know Fact: In patients with CrCl < 30 mL/min, extend the dosing interval to 48 hours to prevent accumulation.

Key Takeaways

1. Streptomycin is a first‑generation aminoglycoside with a narrow therapeutic index.
2. Its bactericidal action is concentration‑dependent, targeting the 30S ribosomal subunit.
3. Optimal dosing requires therapeutic drug monitoring to maintain peak > 15 µg/mL and trough < 5 µg/mL.
4. Renal function dictates dosing intervals; no adjustment is needed for hepatic impairment.
5. Ototoxicity and nephrotoxicity are the most common serious adverse effects.
6. Drug interactions with other aminoglycosides, neuromuscular blockers, and nephrotoxic agents can amplify toxicity.
7. Streptomycin remains essential in MDR‑TB regimens and specific severe infections.
8. Pregnancy and lactation require caution; consider alternative agents when possible.
9. Regular audiometry and renal function tests are mandatory during prolonged therapy.
10. Use the mnemonic “PEN” (Peak, Efficacy, Nephrotoxicity) to recall monitoring targets.

Always remember: the therapeutic benefits of streptomycin can be outweighed by its potential for irreversible hearing loss and kidney damage if not carefully monitored and dosed.